Physician profile
Stephen Senenko
NPI 1164784542
$3,486.15
in general payments reported to CMS, 2019-2025
33 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $493 · 2022: $419 · 2023: $340 · 2024: $983 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,573.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $558.11 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $352.02 | 2021-2024 | Airsupra, Farxiga |
| Lilly USA, LLC | $310.17 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $283.77 | 2025 | |
| Glaxosmithkline, LLC. | $245.65 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $213.83 | 2023-2025 | |
| Gilead Sciences, INC. | $185.93 | 2024-2025 | |
| Amgen INC. | $172.39 | 2022-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $154.92 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $138.38 | 2023-2025 | Accrufer |
| Pfizer INC. | $106.47 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $104.63 | 2022 | |
| Merck Sharp & Dohme LLC | $104.47 | 2024-2025 | Gardasil 9, Gardasil, Capvaxive |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.18 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $72.62 | 2024-2025 | Spravato |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $35.93 | 2024-2025 | Voquezna |
| Ucb, INC. | $35.52 | 2024 | Nayzilam |
| Cequr Corporation | $31.90 | 2024 | Cequr Simplicity |
| Verona Pharma, INC. | $25.51 | 2025 | Ohtuvayre |
| Seqirus USA INC | $24.88 | 2025 | Fluad, Flucelvax |
| Novartis Pharmaceuticals Corporation | $23.71 | 2023 | |
| Grifols USA, LLC | $23.30 | 2024 | Prolastin-C Liquid |
| Hologic Sales and Service, LLC | $23.24 | 2024 | Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.95 | 2024 | Jardiance |
| Neurocrine Biosciences, INC. | $20.31 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.32 | 2022 | |
| Dexcom, INC. | $18.78 | 2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $18.76 | 2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $17.84 | 2024 | Auvelity |
| Azurity Pharmaceuticals, INC. | $16.96 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.84 | 2023 | Xifaxan, Trulance |
| Collegium Pharmaceutical, INC. | $13.98 | 2023 | Xtampza |
| Lexicon Pharmaceuticals, INC. | $13.88 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Senenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.